During the study, participants may undergo the Exablate-BBBO procedure, which uses ultrasound waves to create openings in the protective barrier of the brain. Following this, the medication temozolomide is administered. The study will monitor how well the procedure works and check for any side effects. Effectiveness is also observed through MRI, a medical imaging technique used to create detailed pictures of the inside of the body, to see how the tumor responds to the combined treatment.

The purpose of this study is to evaluate the safety of using this combination of treatments for the first time in humans. Before receiving these treatments, patients will have completed standard radiation therapy for their condition. The study will involve collecting some of the patient’s blood cells through a process called leukapheresis, which are then modified in a laboratory. The dendritic cells will be prepared and given to the patient first through skin injections, and then the modified T cells will be administered into the brain fluid system. Throughout the study, patients will be monitored closely for any side effects or complications that may occur.

The study will also look at how well patients tolerate the full treatment regimen and whether they are able to receive all planned doses of both the dendritic cells and the modified T cells. Doctors will track how the immune system responds to the treatment by examining blood and spinal fluid samples at different time points. They will also monitor the tumor using imaging scans and assess how patients are functioning in their daily lives. The study will follow patients to see how long they survive and how long they live without their disease getting worse, comparing these results to information from other patients who received standard treatment.

The purpose of this study is to find the right dose of ONC206 that can be given safely to patients and to check whether the medication reaches the tumor tissue in the brain. The study is divided into different groups based on the type of tumor and previous treatments. Some patients will receive ONC206 alone, while others will receive it together with radiation therapy, which is a treatment that uses high-energy rays to target cancer cells. Some participants will receive ONC206 with a second course of radiation therapy if their tumor has grown back. There is also a part of the study that will measure how much of the medication gets into the tumor tissue by comparing it to the levels found in the blood before surgery.

During the study, patients will take ONC206 regularly and will have blood tests to check how the body processes the medication and to monitor for any side effects. Patients will also have imaging scans to see how the tumor responds to treatment. Some participants will need to provide tumor tissue samples that were collected during their standard medical care so researchers can study how the medication works in the tumor. The study will continue to monitor patients over time to gather information about safety and how well the treatment works.

The purpose of the study is to develop an optimal treatment plan for children with DIPG by identifying important molecular markers and adjusting the type of medication accordingly. The study will assess the safety and effectiveness of Sirolimus and Trametinib in treating DIPG. Participants will receive these medications either alone or in combination, depending on their specific tumor characteristics. The study will monitor the overall survival of participants from the time of diagnosis and evaluate the safety of Sirolimus when used during radiotherapy and in combination with Trametinib after irradiation.

Throughout the study, the progression of the disease will be closely monitored, and the response to treatment will be assessed using MRI scans every two months. Additionally, the quality of life of participants will be evaluated using a pediatric quality of life inventory. The study will also compare the safety of treatment with Sirolimus alone versus in combination with Trametinib. The estimated end date for the study is June 2026.

The purpose of the study is to see if this new treatment can be safely produced and given to children with these brain tumors, either alongside their regular treatment or after they have completed other therapies. The study will also look at how safe the treatment is for the patients. During the study, participants will receive the treatment through a series of injections over a period of time. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the new treatment.

Throughout the study, researchers will monitor the patients to see how they respond to the treatment and to check for any side effects. The study aims to understand how the treatment affects the patients’ overall health and quality of life. This research is important for finding new ways to help children with these difficult-to-treat brain tumors.

The purpose of this study is to evaluate how well these combination therapies work in patients with DMGs. The study will be conducted in different phases, where participants will receive the combination of ONC201 and Paxalisib at various stages of their treatment journey. This includes those who are newly diagnosed, those who have completed radiation therapy, and those whose tumors have returned. The study aims to see if these treatments can help patients live longer without their disease getting worse.

Participants in the study will take the medications in capsule form, which means they will swallow them. The study will monitor the participants over time to assess the effectiveness of the treatment. The goal is to determine if the combination of ONC201 and Paxalisib can improve the outcomes for patients with these challenging brain tumors. The study is expected to continue until early 2026, with the hope of finding a more effective treatment option for those affected by DMGs and DIPGs.

Participants in the study will receive either a combination of radiotherapy, nimotuzumab, and vinorelbine, or a series of radiotherapy sessions with the same medications. The study will observe how well the tumor responds to these treatments over a period of 36 weeks. The goal is to determine which approach provides the best response in shrinking or controlling the tumor.

The study will also monitor other important outcomes, such as the time until the disease progresses, any recurrence of the tumor, the development of any new cancers, and overall survival. This information will help researchers understand the potential benefits and risks of using nimotuzumab and vinorelbine in treating DIPG, and may guide future treatment options for this challenging condition.

The purpose of the study is to evaluate the safety and effectiveness of AloCelyvir in treating these conditions. For patients with newly diagnosed DIPG, the study will test the combination of AloCelyvir with radiotherapy, which is a treatment that uses high-energy rays to target and kill cancer cells. For those with Medulloblastoma that has returned or worsened, the study will test AloCelyvir on its own. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein.

The study will involve regular visits to monitor the participants’ health and response to the treatment. The goal is to understand how well the treatment works and to ensure it is safe for use in children, adolescents, and young adults. The trial will also look at how the body reacts to the treatment over time, including any side effects that may occur. This research aims to provide new insights into potential treatments for these challenging brain tumors.

Participants in the study will receive either ONC201 or everolimus in combination with radiotherapy. ONC201 is a capsule, while everolimus is available in tablet form under the brand names Afinitor and Votubia. The study will monitor how long patients live without the disease getting worse, which is known as progression-free survival. The trial will also assess the safety of the treatments and any side effects that may occur during the study period.

The study will follow participants over time to gather information on how well the treatments work and their safety. This information will help determine the best treatment options for patients with these types of brain tumors. The trial is expected to continue until 2031, providing valuable insights into the management of DIPG and related tumors.